Bayer Spring Investor Conference March 16 Will Stress 2004 Financial Upturn
This article was originally published in The Pink Sheet Daily
Restructuring is seen as a key factor in Bayer's improved performance. Its U.S. oncology business and ex-U.S. Levitra promotion are among likely topics for updates at the investor meeting.
You may also be interested in...
Bayer purchases GlaxoSmithKline's co-promotion rights to the erectile dysfunction agent "in most major markets outside the U.S.," nearly four months after selling the U.S. marketing rights to its primary care products, including Levitra, to Schering-Plough.
Company plans to eliminate 110 jobs at West Haven, Conn. facility and 440 in Germany, resulting in cost savings of over $170 mil. R&D projects in anti-infectives and urology could be out-licensed.
Bayer is setting up a new oncology division in West Haven, Conn. as the focus of its U.S. prescription drug business following a Sept. 13 licensing deal with Schering-Plough